---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069195"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:51:49.384210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025

## Summary
- Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.
- Phase 2 MaGic gMG trial enrolled 65 patients; top-line results expected September 2025.
- Phase 3 CAPTIVATE CIDP trial ongoing; interim responder analysis 2H'26.
- Phase 2 MoMeNtum MMN trial ongoing; top-line results 2H'26.
- Appointed John C. King as CCO and Sujay Kango to Board of Directors.

## SEC filing metadata
- accession: 0000950170-25-069195
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/0000950170-25-069195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/dnth-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069195
- JSON: https://secwatch.observer/filing/0000950170-25-069195.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.